Author Affiliations: Department of Neurology, The Johns Hopkins Hospital, and Department of International Health, The Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland (Dr Mateen); and Faculty of Health Sciences, University of Ottawa, Ottawa, Ontario, Canada (Dr Mills).
Although antiretroviral therapy has had a major effect on improving the survival of individuals with human immunodeficiency virus (HIV), cognitive disorders related to HIV remain an important burden of disease and disability worldwide. Among the more than 30 million adults living with HIV worldwide, a substantial proportion is estimated to have some form of HIV-associated neurocognitive disorders encompassing HIV dementia, mild neurocognitive impairment, and asymptomatic neurocognitive impairment.1 Conservative estimates from better resourced countries suggest that the number of individuals of all ages living with HIV-related cognitive disorders will increase 5- to 10- fold by 2030.2 Although data from Africa are sparse, 30% of the HIV-infected population in 1 Ugandan outpatient clinic experienced some form of HIV-associated cognitive loss.3
Mateen FJ, Mills EJ. Aging and HIV-Related Cognitive Loss. JAMA. 2012;308(4):349–350. doi:10.1001/jama.2012.8538
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: